個案總覽

The founder of the Access to Medicine Foundation, based in the Netherlands, had a goal to research and publish a biannual, global survey of pharmaceutical companies and their rankings, in terms of their effects in providing needed medicines to people in developing countries. When the first two iterations of the Access to Medicine Index (ATMI) were published in 2008 and 2010 (see case A), the most prominent challenges were engaging stakeholders-government, pharmaceutical firms, nonprofit organizations, investors, and others-and securing funding to support ongoing research and analyses. In 2016, the founder was preparing for the ATMI's fifth iteration (see case B, W17013), and he had a three-point focus: to improve engagement with pharmaceutical companies in an effort to increase the effect of the ATMI on companies' practices; to incorporate the views of patients into the ATMI; and to engage with governments and regulators in the developing countries, where citizens were in need of access to medicines.

Supplement to case W17012.

The founder of the Access to Medicine Foundation, based in the Netherlands, had a goal to research and publish a biannual, global survey of pharmaceutical companies and their rankings, in terms of their effects in providing needed medicines to people in developing countries. When the first two iterations of the Access to Medicine Index (ATMI) were published in 2008 and 2010 (see case A), the most prominent challenges were engaging stakeholders—government, pharmaceutical firms, nonprofit organizations, investors, and others—and securing funding to support ongoing research and analyses. <br>In 2016, the founder was preparing for the ATMI’s fifth iteration (see case B, 9B17M011), and he had a three-point focus: to improve engagement with pharmaceutical companies in an effort to increase the effect of the ATMI on companies’ practices; to incorporate the views of patients into the ATMI; and to engage with governments and regulators in the developing countries, where citizens were in need of access to medicines.

Supplement for product 9B17M010.